298 related articles for article (PubMed ID: 8137188)
1. Cost-effectiveness of enoxaparin versus warfarin prophylaxis against deep-vein thrombosis after total hip replacement.
O'Brien BJ; Anderson DR; Goeree R
CMAJ; 1994 Apr; 150(7):1083-90. PubMed ID: 8137188
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of enoxaparin vs low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery.
Menzin J; Colditz GA; Regan MM; Richner RE; Oster G
Arch Intern Med; 1995 Apr; 155(7):757-64. PubMed ID: 7695464
[TBL] [Abstract][Full Text] [Related]
3. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
Haentjens P; De Groote K; Annemans L
Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
[TBL] [Abstract][Full Text] [Related]
4. Warfarin vs enoxaparin for deep venous thrombosis prophylaxis after total hip & total knee arthroplasty: a cost comparison.
Garcia-Zozaya I
J Ky Med Assoc; 1998 Apr; 96(4):143-8. PubMed ID: 9577110
[TBL] [Abstract][Full Text] [Related]
5. Out of hospital antithrombotic prophylaxis after total hip replacement: low-molecular-weight heparin, warfarin, aspirin or nothing? A cost-effectiveness analysis.
Sarasin FP; Bounameaux H
Thromb Haemost; 2002 Apr; 87(4):586-92. PubMed ID: 12008939
[TBL] [Abstract][Full Text] [Related]
6. Cost implications of low molecular weight heparins as prophylaxis following total hip and knee replacement.
Bell GK; Goldhaber SZ
Vasc Med; 2001; 6(1):23-9. PubMed ID: 11358156
[TBL] [Abstract][Full Text] [Related]
7. A probabilistic cost-effectiveness analysis of enoxaparin versus unfractionated heparin for the prophylaxis of deep-vein thrombosis following major trauma.
Lynd LD; Goeree R; Crowther MA; O'Brien BJ
Can J Clin Pharmacol; 2007; 14(2):e215-26. PubMed ID: 18000316
[TBL] [Abstract][Full Text] [Related]
8. Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. An economic perspective.
Hull RD; Raskob GE; Pineo GF; Feldstein W; Rosenbloom D; Gafni A; Green D; Feinglass J; Trowbridge AA; Elliott CG
Arch Intern Med; 1997 Feb; 157(3):298-303. PubMed ID: 9040296
[TBL] [Abstract][Full Text] [Related]
9. Postoperative deep vein thrombosis prophylaxis: a retrospective analysis in 1000 consecutive hip fracture patients treated in a community hospital setting.
Ennis RS
J South Orthop Assoc; 2003; 12(1):10-7. PubMed ID: 12735619
[TBL] [Abstract][Full Text] [Related]
10. Results of an economic model to assess the cost-effectiveness of enoxaparin, a low-molecular-weight heparin, versus warfarin for the prophylaxis of deep vein thrombosis and associated long-term complications in total hip replacement surgery in the United States.
Botteman MF; Caprini J; Stephens JM; Nadipelli V; Bell CF; Pashos CL; Cohen AT
Clin Ther; 2002 Nov; 24(11):1960-86; discussion 1938. PubMed ID: 12501885
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of enoxaparin versus low-dose heparin for prophylaxis against venous thrombosis after major trauma.
Devlin JW; Petitta A; Shepard AD; Obeid FN
Pharmacotherapy; 1998; 18(6):1335-42. PubMed ID: 9855335
[TBL] [Abstract][Full Text] [Related]
12. Consortium data: comparative efficacy of low molecular weight heparin and warfarin following total hip replacement.
Colwell CW
Orthopedics; 1995 Jul; 18 Suppl():21-3. PubMed ID: 7479422
[TBL] [Abstract][Full Text] [Related]
13. A pharmacoeconomic assessment of enoxaparin and warfarin as prophylaxis for deep vein thrombosis in patients undergoing knee replacement surgery.
Hawkins DW; Langley PC; Krueger KP
Clin Ther; 1998; 20(1):182-95. PubMed ID: 9522114
[TBL] [Abstract][Full Text] [Related]
14. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation.
Hull R; Raskob G; Pineo G; Rosenbloom D; Evans W; Mallory T; Anquist K; Smith F; Hughes G; Green D
N Engl J Med; 1993 Nov; 329(19):1370-6. PubMed ID: 8413432
[TBL] [Abstract][Full Text] [Related]
15. Preventing DVT following total knee replacement: a review of recent clinical trials.
Fitzgerald RH
Orthopedics; 1995 Jul; 18 Suppl():10-1. PubMed ID: 7479418
[TBL] [Abstract][Full Text] [Related]
16. A probabilistic cost-effectiveness analysis of enoxaparin versus unfractionated heparin for the prophylaxis of deep-vein thrombosis following major trauma.
Lynd LD; Goeree R; Crowther MA; O'Brien BJ
Can J Clin Pharmacol; 2007; 14(2):e215-26. PubMed ID: 17652767
[TBL] [Abstract][Full Text] [Related]
17. Economic evaluation of enoxaparin as postdischarge prophylaxis for deep vein thrombosis (DVT) in elective hip surgery.
Davies LM; Richardson GA; Cohen AT
Value Health; 2000; 3(6):397-406. PubMed ID: 16464199
[TBL] [Abstract][Full Text] [Related]
18. Enoxaparin. A pharmacoeconomic appraisal of its use in thromboembolic prophylaxis after total hip arthroplasty.
Dunn CJ; Goa KL
Pharmacoeconomics; 1996 Aug; 10(2):179-90. PubMed ID: 10163420
[TBL] [Abstract][Full Text] [Related]
19. Outpatient treatment of venous thromboembolism with low-molecular-weight heparin: an economic evaluation.
Huse DM; Cummins G; Taylor DC; Russell MW
Am J Manag Care; 2002 Jan; 8(1 Suppl):S10-6. PubMed ID: 11822346
[TBL] [Abstract][Full Text] [Related]
20. The post-discharge prophylactic management of the orthopedic patient with low-molecular-weight heparin: enoxaparin.
Nilsson PE; Bergqvist D; Benoni G; Björgell O; Fredin H; Hedlund U; Nicolas S; Nylander G
Orthopedics; 1997 Feb; 20 Suppl():22-5. PubMed ID: 9048404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]